Compare MYSZ & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | CANF |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.5M |
| IPO Year | N/A | N/A |
| Metric | MYSZ | CANF |
|---|---|---|
| Price | $0.85 | $4.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | 276.4K | ★ 567.7K |
| Earning Date | 11-14-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,512,000.00 | $560,000.00 |
| Revenue This Year | $18.06 | $461.72 |
| Revenue Next Year | $36.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.73 | $3.36 |
| 52 Week High | $3.04 | $46.60 |
| Indicator | MYSZ | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 47.05 | 76.89 |
| Support Level | $0.82 | $3.87 |
| Resistance Level | $0.88 | $4.43 |
| Average True Range (ATR) | 0.07 | 0.40 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 17.81 | 67.26 |
My Size Inc is a USA-based technology company that focuses on the development of an application that assists the consumer to accurately take the measurements of his or her own body to fit clothing without the need to try them on using a smartphone. The purpose of the company's business is to simplify the process of clothing acquisition through the Internet and to significantly reduce the rate of returns of clothing which were acquired through the internet and which are returned to the stores because of ill-fitting. The company generates its revenue through selling products to customers and licensing cloud-enabled software subscriptions, associated software maintenance, and support.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.